At Alimentiv, we constantly strive to provide safer and more non-invasive methods for disease activity assessment. Advanced imaging modalities such as magnetic resonance imaging (MRI)/enterography (MRE) and intestinal ultrasound (IUS) are transforming the way clinical trials assess gastrointestinal and liver diseases.
These non-invasive techniques provide detailed images and quantitative biomarkers that enhance patient stratification, disease monitoring, and endpoint reliability—without the risks of radiation or invasive procedures. By integrating MRI/MRE and IUS into clinical trial protocols, sponsors can improve data quality, reduce patient burden, and streamline study execution.
We offer MRI/MRE as a non-invasive imaging option. MRE has high diagnostic accuracy, does not require exposure to ionizing radiation, and is considerably less invasive than endoscopy, making it an ideal option for serial assessments in clinical trials.
Indications:
Scoring Indices:
In addition to MRE, we also offer IUS, which is a cost-effective, tolerable, and repeatable non-invasive monitoring tool that has shown great accuracy in assessing inflammatory bowel disease (IBD) activity and complications. It may also detect early treatment responses that routine colonoscopy cannot identify.
Alimentiv and the International Bowel Ultrasound (IBUS) Group e.V have a shared mission to advance IUS research and clinical applicability. Alimentiv partners with IBUS to deliver quality IUS central reading services in clinical trials of individuals with IBD.
Our partnership aims to deliver synergistic value to IBD research by combining our clinical trial design expertise and intestinal ultrasound. Together, we work to advance knowledge and experience in the field of IUS for patients with IBD.
See our publications.
Back
